05.02.11
Peapack, NJ-based Pfizer and Kohlberg Kravis Roberts & Co L.P. (KKR) entered into an agreement in early April in which an affiliate of KKR acquired Pfizer’s Capsugel business for $2.375 billion in cash. Capsugel, a world leader in hard capsules and an innovator in drug-delivery systems, generated approximately $750 million in revenue and manufactured more than 180 billion hard capsules in 2010.
“The transaction is an endorsement of Capsugel’s consistent success to date and its potential for future growth with KKR, a firm with deep industry expertise and a long history of partnering with market-leading businesses to take them to the next level,” said Guido Driesen, president and general manager of Capsugel. “Capsugel’s employees and I are excited to work with KKR and eager to enhance the value of our business in partnership with our customers.”
During the past 34 years, KKR has invested in more than 185 transactions with a total value of more than $435 billion. KKR’s current private equity portfolio includes more than 60 portfolio companies with more than $210 billion of annual revenues and more than 900,000 employees.
“The transaction is an endorsement of Capsugel’s consistent success to date and its potential for future growth with KKR, a firm with deep industry expertise and a long history of partnering with market-leading businesses to take them to the next level,” said Guido Driesen, president and general manager of Capsugel. “Capsugel’s employees and I are excited to work with KKR and eager to enhance the value of our business in partnership with our customers.”
During the past 34 years, KKR has invested in more than 185 transactions with a total value of more than $435 billion. KKR’s current private equity portfolio includes more than 60 portfolio companies with more than $210 billion of annual revenues and more than 900,000 employees.